Résilience - COVID-19 - Résilience - Coronavirus disease 2019

Comparison of the role of systemic and mucosal IgA/IgM in the pathophysiology and severity of COVID-19 – COVIDIgS

Submission summary

The mucosal immune response is the first line of defense in respiratory infections such as SARS-CoV-2. The COVIDIgS project aims to characterize the functional properties of this response and in particular the IgA response against SARS-CoV-2 variants. COVIDIgS benefits for this purpose from access to a prospective cohort of patients at different stages of COVID-19 pathology and vaccinated healthcare workers. The main objectives of the project are to understand the potential role of serum and mucosal IgA in the immunopathology of COVID-19 but also to identify important features of this response in predictive preclinical models of reconstituted human epithelium that can contribute to the evaluation of vaccine candidates and the development of putative mucosal immunotherapy approaches.

Project coordination

Stéphane PAUL (CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

UJM CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE

Help of the ANR 79,968 euros
Beginning and duration of the scientific project: May 2021 - 12 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter